Is NCCN up or down today?
NCCN is down 0.95% today, last at 86.08. This stock moved -0.95% versus the prior close.
NCCN · NCCN
NCCN (NCCN) is trading at 86.08, down 0.95% on the session. NCCN sits at the 50% mark of its 52-week range.
Leading the coverage: “NCCN Lists Gedatolisib Regimens as Preferred Option in HR+/HER2– Metastatic Breast Cancer - Targeted Oncology” (Google News Company, 43d ago). NCCN is -6.18% since story.
NCCN trades on a trailing P/E of 21.9.
Analyst firms are mostly reiterating — no strong directional shift lately.
NCCN is down 0.95% today, last at 86.08. This stock moved -0.95% versus the prior close.
Leading the coverage: “NCCN Lists Gedatolisib Regimens as Preferred Option in HR+/HER2– Metastatic Breast Cancer - Targeted Oncology” (Google News Company, 43d ago). NCCN is -6.18% since story. Dominant story: SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits (1 source, bullish) RSI unavailable Price sits at 50% of its 52-week range Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Historical price chart unavailable
Live quote in the header is real, but OHLC history could not be loaded from Yahoo Finance or fallback providers. Charts use Yahoo when configured correctly — check server logs for provider errors.
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits
Cancer Drug Shortages Persist Into Fourth Year, NCCN Data Show - The American Journal of Managed Care
New NCCN Survey Highlights Persistent Cancer Medication Shortages Across United States - PR Newswire
NCCN and Flatiron Health Announce Renewal of Collaboration to Advance Real-World Data Research Across Leading Cancer Centers - BioSpace
NCCN recommends Signatera for bladder cancer treatment - scanx.trade